Liens utiles

Institut National du Cancer agence d'expertise sanitaire et scientifique en cancérologie

Nota Bene Cancer bulletin de veille bibliographique dans les divers domaines de la recherche sur les cancers

Onco Actu brèves sur le web anglophone


Tous les liens utiles


Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study

Annals of Oncology Advance Access, 21 juillet 2010, n° 7, 1448-1454

P. Marino, C. Siani, H. Roché, C. Protière, P. Fumoleau, M. Spielmann, A-L. Martin, P. Viens, A-G. Le Corroller Soriano


Using data from the PACS 01 randomized trial, we evaluated the cost-effectiveness of anthracyclines plus docetaxel (Taxotere; FEC-D) versus anthracyclines alone (FEC100) in patients with node-positive breast cancer.

Patients and Methods

Costs and outcomes were assessed in 1996 patients and the incremental costeffectiveness ratios (ICERs) were estimated, using quality-adjusted life years (QALYs) as outcome. To deal with uncertainty due to sampling fluctuations, confidence regions around the ICERs were calculated and cost-effectiveness acceptability curves were drawn up. Sensitivity analyses were also carried out to assess the robustness of conclusions.


The mean cost of treatment was 33% higher with strategy FEC-D, but this difference decreased to 18% at a 5-year horizon. The ICER of FEC-D versus FEC100 was estimated to be 9665€ per QALY gained (95% confidence interval €2372–€55 515). The estimated probability that FEC-D was cost-effective reached >96% for a threshold of €50 000 per QALY gained. If the price of taxane decreased slightly, the ICER would reach some very reasonable levels and this strategy would therefore be much more cost-effective.


The sequential use of FEC100 followed by docetaxel appears to be a cost-effective alternative, even when uncertainty is taken into account.

More informations